Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

GTX-101

Small molecule · developed by Grace Therapeutics

Phase 1 Most advanced trial (none active)

GRCE Developer

1 Registered trials

What is GTX-101?

GTX-101 is a bupivacaine hydrochloride metered spray. It is studied in postherpetic neuralgia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Bupivacaine HCl metered spray
Drug type: Small molecule
Therapy area: Neurology
Developer: Grace Therapeutics Inc. (GRCE)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05517486	Phase 1	Postherpetic Neuralgia	Unknown	GRCE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Postherpetic Neuralgia

More from Grace Therapeutics

GTX-104 Phase 3

Sources

ClinicalTrials.gov NCT05517486

Updated Oct 11, 2026. Something wrong or missing? Report it on the GRCE page.

Follow GRCE, the company behind GTX-101

See GRCE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GRCE catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z